Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1/2 1Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1

Conditions

Multiple Myeloma 41Neoplasms, Plasma Cell 16Lymphoma, Non-Hodgkin 13Lymphoma 13Leukemia, Myeloid, Acute 13Leukemia 13Myelodysplastic Syndromes 11Hodgkin Disease 10Lymphoma, Mantle-Cell 8Precursor Cell Lymphoblastic Leukemia-Lymphoma 7Lymphoma, Follicular 7Leukemia, Lymphocytic, Chronic, B-Cell 6Lymphoma, Large B-Cell, Diffuse 5Leukemia, Myelogenous, Chronic, BCR-ABL Positive 5Congenital Abnormalities 4Neuroblastoma 3Melanoma 3Lymphoma, B-Cell, Marginal Zone 3Leukemia, Myeloid, Accelerated Phase 3Leukemia, Biphenotypic, Acute 3Hematologic Neoplasms 3Graft vs Host Disease 3Burkitt Lymphoma 3Smoldering Multiple Myeloma 2Neoplasms 2Myeloproliferative Disorders 2Lymphoma, T-Cell 2Lymphoma, Large-Cell, Immunoblastic 2Lymphoma, B-Cell 2Leukemia, Myelomonocytic, Juvenile 2

Interventions

ruxolitinib 1filanesib 1Stem Cell Transplantation 1Melphalan 1Clofarabine 1CPI-0610 1Alemtuzumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Preleukemia × Melphalan × Clear all
NCT00943592 2014-02-27

Clofarabine-Melphalan-Alemtuzumab Conditioning in Patients With Advanced Hematologic Malignancies

University of Chicago

Phase 1/2 Completed
82 enrolled 12 charts
Other hematologic neoplasm

Leukemia, Preleukemia

Data powered by HemOnc (CC BY 4.0) Colophon âš¡